Clinical Trials in North Carolina

Showing 3301-3320 of 9,731 trials

Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation

NCT03879239

The study is a prospective, randomized, multicenter, adaptive design, double blinded, placebo-controlled study, to evaluate the efficacy and safety of Vibrant Capsule vs. placebo in relieving constipation in subjects with Chronic Idiopathic Constipation.

Chronic Idiopathic Constipation

Vibrant Ltd.349 participantsStarted Apr 2019

Foley, Alabama, United States • Tucson, Arizona, United States • Augusta, Georgia, United States +5 more locations

COMPLETEDPhase 1/231 miles

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

NCT01712217

The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer(NSCLC)

Astex Pharmaceuticals, Inc.220 participantsStarted Oct 2012

Scottsdale, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +62 more locations

Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Find Trials by Condition in North Carolina

Computational Psychiatric Approach to Depression

Comparative Effectiveness of FITs With Colonoscopy

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

The clonoSEQ® Watch Registry

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Hypertrophic Cardiomyopathy Federated Learning Implementation Platform

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

Training for Health Professionals In Tanzania